

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Holger G. Gassner et al. Art Unit : Unknown
Serial No. : Examiner : Unknown
Filed :
Title : METHODS FOR ENHANCING WOUND HEALING

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

Please insert the following paragraph at page 1, line 3:

--CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Serial No. 09/807,793, filed April 18, 2001, which is a 35 U.S.C. §371 application of PCT/US99/24182, which claims priority from U.S. Serial No. 60/105,688, filed October 27, 1998.--

In the claims:

Cancel claims 1-22 and 24-31.

Please amend claim 23 as follows:

23. (Amended) A composition comprising a botulinum toxin, a local anesthetic agent, and a local vasoconstrictive agent.

Please add new claims 32-43.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No EL639959418US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the U S. Patent & Trademark Office, P.O. Box 2327, Arlington, VA 22202

Date of Deposit

Signature

Vince Defante

Typed or Printed Name of Person Signing Certificate

33. (new) The composition of claim 32, wherein said botulinum toxin is botulinum toxin A.

34. (new) The composition of claim 32, wherein said botulinum toxin is botulinum toxin B.

35. (new) The composition of claim 23, wherein said local anesthetic is lidocaine, bupivacaine, or mepivacaine.

36. (new) The composition of claim 23, wherein said local vasoconstrictive agent is epinephrine.

37. (new) A composition comprising botulinum toxin and a local anesthetic.

38. (new) The composition of claim 37, wherein said botulinum toxin is selected from the group consisting of botulinum toxin A, B, C, D, E, F, and G.

39. (new) The composition of claim 37, wherein said local anesthetic is lidocaine, bupivacaine, or mepivacaine.

40. (new) The composition of claim 37, said composition further comprising a local vasoconstrictive agent.

41. (new) The composition of claim 40, wherein said local vasoconstrictive agent is epinephrine.

42. (new) A composition comprising a botulinum toxin and a local vasoconstrictive agent.

Parameter	Unit	Value
Mean	mm	1.0
Standard deviation	mm	0.2
Minimum	mm	0.5
Maximum	mm	1.5
Range	mm	1.0
Median	mm	1.0
Mode	mm	1.0
Skewness		0.0
Kurtosis		0.0
Correlation coefficient		1.0
Chi-square		0.0
Degrees of freedom		1
P-value		0.0
Significance level		0.05
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		0.0
Rejection region		0.0
Power of test		0.0
Effect size		0.0
Sample size		100
Population size		1000
Sampling error		0.0
Margin of error		0.0
Confidence interval		0.95
Test statistic		0.0
Acceptance region		

43. (new) The composition of claim 42, wherein said local vasoconstrictive agent is epinephrine.--

10631-230550


REMARKS

Applicant has canceled claims 1-22 and 24-31, and amended claim 23 to recite botulinum toxin. New claims 32-43 have been added, which relate to compositions containing botulinum toxin. Support for these claims can be found, for example, at page 3, lines 5-6, and page 9, lines 30-34, of the published PCT application. Applicant notes that claims 23 and 32-43 correspond with claims restricted to Group II of the parent application (U.S. Serial No. 09/807,793). Applicant asks that claims 23 and 32-43 be examined. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

11/26/01



Monica McCormick Graham, Ph.D.
Reg. No. 42,600

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60061213.doc

T09011 205550

Version with markings to show changes made

In the claims:

Claims 1-22 and 24-31 have been canceled.

Claim 23 has been amended as follows:

23. (Amended) A composition comprising a [chemodenervating agent] botulinum toxin,
a local anesthetic agent, and a local vasoconstrictive agent.

07039-171002-2305550